Holen Sie sich die Stockscreener-App
0.3617
5.44%
-0.0208
Handel nachbörslich:
.35
-0.0117
-3.23%
Schlusskurs vom Vortag:
$0.3825
Offen:
$0.39
24-Stunden-Volumen:
835.37K
Relative Volume:
0.04
Marktkapitalisierung:
$17.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.39M
KGV:
-0.2153
EPS:
-1.6803
Netto-Cashflow:
$-2.09M
1W Leistung:
+4.12%
1M Leistung:
-5.76%
6M Leistung:
+6.38%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.3525
$0.39
1-Wochen-Bereich:
$0.35
$0.4691
52-Wochen-Spanne:
$0.2012
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Firmenname
Aspire Biopharma Holdings Inc
Sektor
Branche
Telefon
561-704-8527
Adresse
194 CANDELARO DRIVE, #233, HUMACAO
Vergleichen Sie ASBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.3617 | 18.94M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aspire Biopharma Holdings Inc Aktie (ASBP) Neueste Nachrichten
A look into Aspire Biopharma Holdings Inc (ASBP)’s deeper side - setenews.com
What drives Aspire Biopharma Holdings Inc stock priceSell Signals and Alerts & Rapid Portfolio Investment - earlytimes.in
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - The Daily Jeffersonian
Working capital per share of Aspire Biopharma Holdings, Inc. – NASDAQ:ASBP - TradingView
Aspire Biopharma Faces Nasdaq Delisting Notice - MSN
Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall By Investing.com - Investing.com Australia
Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall - Investing.com India
Aspire Looks To Key Milestones For Sublingual Aspirin And Semaglutide - insights.citeline.com
Aspire Biopharma Holdings Inc Equity Warrant Stock Analysis and ForecastEarnings Call Summaries & High Profit Market Ideas - earlytimes.in
Aspire Biopharma files omnibus patent for sublingual delivery tech By Investing.com - Investing.com Canada
Is Aspire Biopharma Holdings Inc a good long term investmentResistance Zone Identification & Free Stock Predictions and Analysis - earlytimes.in
Aspire Biopharma files omnibus patent for sublingual delivery tech - Investing.com
Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform - ACCESS Newswire
Penny Stocks To Watch Today – October 2nd - Defense World
Aspire Biopharma Hldgs Stock Price, Quotes and Forecasts | NASDAQ:ASBP - Benzinga
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity ConferenceOctober 8-9, 2025 - ACCESS Newswire
Why Actelis Networks Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket - Benzinga
Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher - inkl
Stock Market Update: Nasdaq's Most Active Stocks on Oct 2, 2025News and Statistics - IndexBox
Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results - Benzinga
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket - Benzinga
Aspire Biopharma outlines pipeline milestones for drug delivery tech By Investing.com - Investing.com Australia
Aspire Biopharma outlines pipeline milestones for drug delivery tech - Investing.com
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication - ACCESS Newswire
Breakthrough 2-Minute Heart Attack Treatment: Aspire's Sublingual Aspirin Beats Standard Tablets in Clinical Tests - Stock Titan
Is There Hidden Value in Modern Engineering and Projects Limiteds Business ModelQuarterly Earnings Review & Double Digit Trading Ideas - earlytimes.in
What drives Aspire Biopharma Holdings Inc Equity Warrant stock priceCandlestick Trading Patterns & Best Stocks For Explosive Growth - earlytimes.in
What analysts say about Aspire Biopharma Holdings Inc stockShort-Term Trading Alerts & Free Powerful Profit Generation - earlytimes.in
What analysts say about Aspire Biopharma Holdings Inc Equity Warrant stockResistance Zone Identification & Register for the Next Free Workshop - earlytimes.in
How Star Equity Holdings Inc. (FDV0) stock trades after earningsIPO Watch & Reliable Breakout Forecasts - newser.com
Aspire Biopharma Holdings Inc Stock Analysis and ForecastPrice-to-Earnings Ratio Insights & Minimal Investment Capital - earlytimes.in
Aspire Biopharma completes $1 million funding tranche and changes auditor By Investing.com - Investing.com Australia
Aspire Biopharma completes $1 million funding tranche and changes auditor - Investing.com
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Detroit Free Press
Aspire Biopharma Holdings, Inc. Announces CEO Transition - Foster's Daily Democrat
Aspire Biopharma files to sell 147.18M shares of common stock for holders - MSN
Aspire Biopharma Enlists Fitness Influencers To Promote Pre-Workout Product - Net Influencer
Aspire Biopharma secures initial order for preworkout supplement, part of agreement with SupraNatural - MSN
Aspire Biopharma Holdings Inc (NASDAQ: ASBP) 8.11% Incline Turns Away Investor Interest In Company’s Stock - stocksregister.com
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product - ACCESS Newswire
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product | FinancialContent - FinancialContent
2-Minute Energy Boost: Aspire's BUZZ BOMB Teams with UFC Champion to Disrupt Pre-Workout Market - Stock Titan
Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement - ACCESS Newswire
2 Million Unit Production Order: Aspire Biopharma Scales BUZZ BOMB Pre-Workout in $27.9B Market - Stock Titan
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement - Fall River Herald News
Can volume confirm reversal in NCR Voyix CorporationEarnings Overview Report & Safe Investment Capital Preservation Plans - newser.com
Finanzdaten der Aspire Biopharma Holdings Inc-Aktie (ASBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):